- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Managing Partial Response: Augmentation Strategies In MDD

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Managing Partial Response: Augmentation Strategies In MDD
Persistent residual symptoms (e.g., sleep disturbances, cognitive symptoms) have known interference on quality of life and functioning of individuals with major depressive disorder (MDD) who respond to or remit from antidepressant treatment.1 Understanding the inherent challenges in symptom recognition and subsequent treatment, clinicians are tasked with finding optimal symptom relief in aiding patients on their journey towards functional recovery.
In this webinar, Dr. Alex Matushek moderates an enlightening discussion on the current state of clinical guidelines in the treatment framework of depression partial response management with Dr. Roueen Rafeyan. They will reflect on recent meta-analyses and current practice guidelines highlighting the optimization of pharmacotherapy to improve outcomes. Join us for this unique opportunity to learn and grow as we all strive to improve the quality of life of those impacted!
References:
1. Zajecka J, et al. Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and
Management. J Clin Psychiatry. 2013;74(4): 407-414.

Roueen Rafeyan, MD
Psychiatrist & Chief Medical Officer for Gateway Foundation Addiction Treatment Centers and an Assistant Professor of Psychiatry at the Feinberg School of Medicine, Northwestern University
More

Alex Matushek, PharmD, MBA
Medical Science Liaison
Roueen Rafeyan, MD is a paid consultant of Otsuka Pharmaceutical Development &
Commercialization, Inc.
Alex Matushek, PharmD, MBA is an employee of Otsuka Pharmaceutical Development & Commercialization,
Inc.